LAG3-Targeting Therapy for Parkinson's Disease: Unlocking Biomarkers, Autoimmunity, and Blood Brain Barrier Strategies

Abstract

LAG3-targeting therapy represents a promising therapeutic approach for the treatment of neurodegenerative diseases such as Parkinson's Disease (PD) through modulation of immune responses and attenuation of neuroinflammatory processes. This therapy leverages the role of lymphocyte-activation gene 3 (LAG3) in the uptake and propagation of pathological α-synuclein, a key protein implicated in PD. However, significant challenges remain, including the identification of reliable biomarkers for early diagnosis and treatment monitoring, understanding the autoimmune implications of LAG3 modulation, and developing effective strategies for crossing the blood-brain barrier (BBB). Addressing these obstacles is crucial for advancing LAG3-based therapies from preclinical studies to clinical applications. This review highlights the potential of LAG3-targeting therapies, elucidates the mechanisms of α-synuclein modulation, and emphasizes the need for further research to enhance precision medicine approaches in PD treatment. By overcoming these challenges, LAG3-targeting therapies may offer new hope for patients and clinicians in managing Parkinson's disease. Inm summary, addressing the complexities surrounding LAG3-targeting therapies is essential for their successful implementation in clinical settings for Parkinson's disease.